triumph-1 retatrutide 🚨 BREAKING: Shows “Bariatric-Level” Weight Loss in Phase 3 Trial New Phase 3 data show retatrutide may deliver weight-loss outcomes approaching those seen with bariatric surgery—marking one of the most Retatrutide Delivers Bariatric-Level Weight Loss

& MacDonald, D

Approximately half of patients treated with GLP1/GIP medication experienced body weight losses of at least 10% and 15%, respectively

Charlotte, N

Achieving goals and taking workouts to the next level is possible naturally

Cardiovascular risk factor improvements (blood pressure, lipids, HbA1c) Any unexpected side effects at longer treatment durations If VANQUISH-1 results confirm 20%+ weight loss with favorable tolerability, VK2735 becomes one of the most compelling obesity drugs in the pipeline not because it beats retatrutide, but because it offers a meaningful step up from tirzepatide with potentially better tolerability